Stenotrophomonas maltophilia is a Gram-negative bacillus that is ubiquitous in the environment. It possesses limited virulence factors but is a significant pathogen in immunocompromised patients with indwelling central venous catheters (CVC) and may colonize the respiratory tract. 1 Management is difficult because of inherent resistance to multiple antibiotics and technical problems in performing and interpreting sensitivity tests. We reviewed our patients with S. maltophilia bacteraemia in a Blood and Marrow Transplant (BMT) and non-BMT haematology setting. Previously we showed a high mortality rate of Gramnegative sepsis in BMT patients. 2 We aimed to define the presenting clinical features and the demographics of patients with S. maltophilia bacteraemia and also the time course for diagnosis and the outcome with different therapeutic manoeuvres.
We conducted a search of our microbiology laboratory database to identify episodes of S. maltophilia bacteraemia from January 1994 to December 2004. Forty-two episodes were identified and the case notes reviewed for 16 BMT and 24 non-BMT haematology patients. Median age was 16 years (range 3 months to 52 years) in BMT and 52 years (22-66 years) in non-BMT patients. The most common underlying diagnosis was leukaemia. Median time from haematological diagnosis to the S. maltophilia bacteraemia was 5 months in the BMT and 4 months in the non-BMT patients. Fifty-five percent of the BMT patients underwent a sibling allograft and the remainder had unrelated allografts. Blood cultures were taken through a central venous (CV) line in 84% but concurrently taken negative sets were not documented.
Thirty-seven of 40 patients were commenced on empiric first-line antibiotics, most commonly piperacillin/tazobactam or ceftriaxone with gentamicin. Most blood cultures (73%) were positive within 48 h and the median time to S.maltophilia identification was 2.5 days using standard methods.
3 In 63% an indwelling CVC was the sole focus of infection as identified by the examining physician. At the time of the bacteraemia the CVC had been in situ for a median duration of 73 and 19 days in the BMT and non-BMT haematology patients respectively. In 86% of the non-BMT haematology patients the line was removed, 71% as a primary response to the bacteraemia. In the BMT patients removal occurred in 81%, half as a primary measure and 31% as a salvage manoeuvre, four in response to further positive blood cultures of which three were with S. maltophilia. Two patients were septic at admission, one of whom went to a high dependency unit.
Four main antibiotic combinations were used, most commonly co-trimoxazole or ceftazidime with ciprofloxacin, although there was no specific protocol during the study period. There were insufficient numbers treated with each regimen to compare outcomes. The median duration of organism-specific treatment was 9 days, considerably shorter than our current recommendation of 14 days. The most common outcome was eradication of bacteraemia and hospital discharge. Death secondary to sepsis occurred in two BMT patients whose lines were not removed, one of whom had skin and soft tissue infection. One non-BMT patient died despite line removal. Overall, infection-related mortality was 7.5%.
We focused on potential risk factors highlighted in previous literature, including neutropaenia, gastrointestinal disease, presence of a urinary catheter or previous antibiotics, surgery or steroids in the preceding month (Figure 1 ). Sixty-nine percent of the BMT and 58% of the haematology patients were neutropaenic (o500 cells/mm 3 ). Gastrointestinal symptoms included diarrhoea and mucositis. Oculo-cutaneous GVHD was present in one patient. This was present for 53 days before the bacteraemia but well controlled. Numbers are too small to draw conclusions regarding risk factors for bacteraemia. All BMT and 58% of non-BMT haematology patients were on prophylactic antibiotics, most commonly ciprofloxacin (28 patients) or co-trimoxazole (14 patients). Eleven of the non-BMT patients were on no prophylaxis.
No current treatment regimen is established for S. maltophilia and current national guidelines recommend susceptibility testing for co-trimoxazole only. 4 Quinolones may be therapeutically active in combination with cotrimoxazole but there are no data to support a relationship between in vitro susceptibility testing and clinical outcome. 5 The 'standard' therapy of co-trimoxazole may be difficult to administer to neutropaenic patients because of myelosuppressive toxicity. More commonly, we have used ceftazidime with ciprofloxacin or moxifloxacin (use restricted because of liver toxicity). A recent systematic review of treatment other than co-trimoxazole found cure or improvement rates of 90, 75 and 66.7% with regimens based around ciprofloxacin, ceftriaxone/ceftazidime or ticarcillin/ticarcillin-clavulanate, respectively. 6 A study of catheter-related bloodstream infections in non-neutropaenic patients with haematological malignancies found a predominance of Gram-negative infections (68%) with S. maltophilia the most common (26%). 7 defeverscence within 48 h of line removal or commencement of broad spectrum antibiotics in all but one patient. All patients were treated with co-trimoxazole. A review found underlying haematological disease and admission to an intensive care unit were independent risk factors for mortality in S. maltophilia infection. 8 In bacteraemic patients, shock and thrombocytopaenia were poor prognostic factors and initial inadequate antimicrobial therapy had no effect. A retrospective study of CVC-related S. maltophillia bacteraemia in haematology and oncology patients identified risk factors including nosocomial bacteraemia, immunosuppressive therapy, CVC-related bacteraemia and neutropaenia. 9 In 92% of patients cure was achieved after removal of the CVC, despite inappropriate antibiotic therapy. Three deaths occurred in situations in which CVC removal was delayed or not performed. Another retrospective cohort study showed Sepsis-related Organ Failure Assessment index 46 and septic shock as independent risk factors for 14-day mortality in patients with S. maltophilia bacteraemia or pneumonia. 10 They found no significant difference in mortality in patients who did or did not receive co-trimoxazole or a situation in which commencement of appropriate antibiotics was delayed.
The significance of S. maltophilia is as a potential cause of failure to respond to first-line antibiotics in patients with neutropaenic sepsis. Our study confirms the importance of S. maltophilia as a cause of CVC-associated bacteraemia in BMT and haematology patients and suggests the need for further prospective study to determine the optimum antibiotic regimen and the significance of manoeuvres such as CVC removal; this should be done on a multicentre basis.
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